143results about How to "Increase cardiac output" patented technology

An implantable stimulator and monitor measures a group of heart failure parameters indicative of the state of heart failure employing EGM signals, measures of blood pressure including absolute pressure P, developed pressure (DP=systolic P-diastolic P), and/or dP/dt, and measures of heart chamber volume (V) over one or more cardiac cycles. These parameters include: (1) relaxation or contraction time constant tau (.tau.); (2) mechanical restitution (MR), i.e., the mechanical response of a heart chamber to premature stimuli applied to the heart chamber; (3) recirculation fraction (RF), i.e., the rate of decay of PESP effects over a series of heart cycles; and (4) end systolic elastance (E.sub.ES), i.e., the ratios of end systolic blood pressure P to volume V. These heart failure parameters are determined periodically regardless of patient posture and activity level. The physician can determine whether a particular therapy is appropriate, prescribe the therapy for a period of time while again accumulating the stored patient data for a later review and assessment to determine whether the applied therapy is beneficial or not, thereby enabling periodic changes in therapy, if appropriate. Drug therapies and electrical stimulation therapies, including PESP stimulation, and pacing therapies including single chamber, dual chamber and multi-chamber (bi-atrial and/or bi-ventricular) pacing can be delivered. In patient's prone to malignant tachyarrhythmias, the assessment of heart failure state can be taken into account in setting parameters of detection or classification of tachyarrhythmias and the therapies that are delivered.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive device may include a biodegradable material that biodegrades to offset flow changes caused by tissue ingrowth. The inventive device may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits.

A method for increasing circulation in a breathing person utilizes a valve system that is interfaced to the person's airway and is configured to decrease or prevent respiratory gas flow to the person's lungs during at least a portion of an inhalation event. The person is permitted to inhale and exhale through the valve system. During inhalation, the valve system functions to produce a vacuum within the thorax to increase blood flow back to the right heart of the person, thereby increasing cardiac output and blood circulation.

Techniques are provided for use with an implantable cardiac stimulation device equipped with a multi-pole left ventricular (LV) lead having a proximal electrode implanted near an atrioventricular (AV) groove of the heart of the patient. A left atrial (LA) cardioelectrical event is sensed using the proximal electrode of the LV lead and a corresponding LA cardiomechanical event is also detected, either using an implantable sensor or an external detection system. The electromechanical activation delay between the LA cardioelectrical event and the corresponding LA cardiomechanical event is determined and then pacing delays are set based on the electromechanical activation delay for use in controlling pacing. The pacing delays can include, e.g., AV delays for use with biventricular cardiac resynchronization therapy (CRT) pacing. Other techniques described herein are directed to exploiting right atrial (RA) cardioelectrical events detected via an RA lead for the purposes of setting pacing delays.

An improved pacemaker has a hysteresis feature that activates accelerated pacing during periods of sinus arrest and/or extreme bradycardia. When the patient's intrinsic heart rate drops below a hysteresis rate, the pacemaker reverts to a programmable accelerated rate or to the average cardiac rate. Accelerated pacing is delivered for a programmable period of time, after which the pacing rate is gradually reduced toward a lower rate. If a desirable intrinsic rate is not attained after the pacing rate is reduced to the lower rate, the intervention cycle repeats.

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.

The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2, NF-AT3, calcineurin, MCIP, and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of many of these factors or the pathways mediated by these factors has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between these factors and the pathways they mediate through a family of non-voltage gated channels called TRP channels. The present invention further demonstrates that inhibitors of TRP channels can inhibit or treat heart failure and cardiac hypertrophy.

This invention discloses a Chinese medicine for treating coronary disease angina pectoris and it's preparation method. Said medicine comprises (wt.%) Astragalus mongholicus 22.2-66.8%, Saliva miltiorrhiza Bge 11.6-33.4%, pseudo-ginseng 2.5-13.5% and Jiangxiang 14.5-44.3%. The preparation process includes taking Saliva miltiorrhiza Bge and pseudo-ginseng to make extract paste, taking Astragalus mongholicus to make extract paste, then taking Jiangxiang to make back-flow extraction and collect volatile oil, uniformly mixing said two extract pastes and the volatile oil and proper supplementary material to obtain the invented medicine which has special curative effect to qi-asthenia blood-stasis type coronary disease.

This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal.

An all-in-one external counterpulsation apparatus and method for minimizing end diastolic pressure that includes an internally housed fluid distribution assembly interconnecting a plurality of inflatable devices adapted to be received about the lower extremities of a patient and an internally housed compressed fluid source to be distributed by the fluid distribution assembly to the inflatable devices. The apparatus includes a curvilinear table with apertures adapted to provide communication between the inflatable devices and the fluid source.

Methods, apparatus, and systems are provided to control contraction of the heart. At least one sensing element receives signals indicating electrical activity of sinus rhythm of the heart. Based on the received signals, the progress of contraction of the heart is determined. Based on the progress of contraction, the chamber of the heart may then be stimulated at a plurality of locations. In another embodiment, a plurality of electrodes are implanted in the left ventricle to stimulate at multiple locations in the left ventricle for the purpose of improving hemodynamic performance and increasing cardiac output in a patient who is suffering from congestive heart failure. A pre-excitation voltage may be applied to pre-condition a portion of the heart. A stimulation pulse of increased current may also be applied to improve cardiac output.

The present invention relates to Chinese medicine and its extracting and processing technology, and is especially the effective part extracted from American ginseng leaf and ginseng leaf and its preparation process. The extracted effective part contains six kinds of ginsenoside substances, including ginsenoside Re, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd. Its preparation process includes water extracting American ginseng leaf and ginseng leaf in the weight ratio of 1 to 0.3, macroporous resin adsorption of the water extract liquid, water eluting to eliminate impurity, further eluting with two kinds of elutents, collecting the eluted liquid, and refining the total solid matter to reach purity up to 63.45 %. The extracted effective part has less side effects, and may be used widely in compound medicine preparation and functional food and for separating ginsenoside substance.

A method for operating a cardiac pacemaker in which the mode of operation of the pacemaker is altered in response to detecting an episode of atrial tachycardia. In accordance with the invention, the pacemaker's pacing mode is altered in a manner that attempts to maintain hemodynamic stability during the atrial tachycardia. Such a mode switch is particularly applicable to pacemaker patients suffering from some degree of congestive heart failure.

Techniques for pacing the heart of a patient as a function of a pressure value make use of a pressure monitor that receives a signal from a pressure sensor in the heart. The pressure monitor measures a pressure value. The pressure monitor may, for example, estimate the pulmonary artery diastolic pressure if the pressure sensor is located in the right ventricle, or calculate the mean central venous pressure if pressure sensor is located in the right atrium. The energy level of the pacing pulses delivered to the patient's heart by a pacemaker is modulated as a function of the pressure value. Modulating the energy level of the pacing pulses modulates the cardiac output of the patient's heart.

The invention provides a compound red sage root freeze dried powder injection containing salvianolic acid B and its preparing process, wherein the injection comprises root of red rooted saliva, notoginseng and borneol, and is prepared through extracting root of red rooted saliva and notoginseng to obtain red sage root extract, pseudo-ginseng extract, dissolving baras camphor with right amount of ethanol, coating with beta-cyclodextrin, charging injection for water into red sage root extract, notoginseng or red sage root and notoginseng extracts for dissolving, boiling, cooling down, filtering, mixing filtrate with baras camphor beta-CD inclusion solution, charging mannitol, adding right amount of water for injection, adjusting pH, and freeze-drying. In the obtained freeze dried injection, calculated by salvianolic acid B (C36H30O16), the content of red sage root 6.25-100.00mg/g freeze-dried powder solid.

The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.

The invention discloses a Chinese medicine combination for treating cardio-cerebral vascular diseases, which is composed of raw materials with the following parts by weight: 30-50 parts of radix astragali, 20-25 parts of angelica, 15-20 parts of hemlock parsley, 30-50 parts of salvia miltiorrhiza, 15-20 parts of pseudo-ginseng, 15-20 parts of hawkthorn and 20-30 parts of radix puerariae; the Chinese medicine combination of the invention has ingenious compatibility, simple prescription, broad source of raw materials, low price as well as the efficacies of tonifying both qi and blood, balancing yin and yang, activating blood circulation and dissolving stasis; the Chinese medicine combination can soften blood vessels through reducing blood fat and blood viscosity and eliminating blood scales and finally achieve the purposes of smoothing blood circulation and activating cardio-cerebral function; furthermore, the Chinese medicine combination has unique efficacy for resisting atherosclerosis as well as significant curative effect on cardio-cerebral vascular diseases like coronary heart disease, cerebral thrombosis, and the like; the total clinical effective rate can reach over 95% and the Chinese medicine combination can achieve good preventive and health care effect through long-term oral administration and has safe oral administration and no toxicity and side effect.

The invention relates to a beverage, in particular to a honey pomelo tea beverage and a preparation method thereof. The tea beverage is characterized by being prepared from the following raw materials by weight: 1200-1500 parts of pomelos, 700-900 parts of hawthorn, 200-500 parts of salt, 200-500 parts of crystal sugar, 400-700 parts of honey, and 2500-3000 parts of water. The honey pomelo tea beverage provided in the invention has the characteristics of being sweet and sour and delicious, as well as nutrient-rich, and frequent drink can achieve the efficacy of promoting appetite and helping digestion, relieving dyspepsia, reducing phlegm and promoting the circulation of qi, softening blood vessels, lowering blood fat, and reducing cholesterol. Being suitable for people of all ages, the honey pomelo tea beverage disclosed in the invention is an ideal green beverage.

The invention relates to a microbiological feed additive and a preparation method and an application thereof, relating to a feed additive. The invention provides a microbiological feed additive compounded with various microbiological fermented powders and a preparation method and an application thereof. The microbiological feed additive consists of the following compounds according to weight percentages: 60%-99% of DHA (Docosahexenoic acid) fermented powder, 0-25% of AA (Arachidonic acid) fermented powder and 1%-30% of R. spkaeroides fermented powder. After the nutrition compositions are mixed uniformly after being crashed respectively; and then sieving, checking, weighing and packing are performed. The microbiological feed additive can be used as an active in aquatic product, poultry and livestock cultivation feeds, and the addition accounts for 0.2%-5.0% of total mass of basal feed. The contents of the nutrition compositions in the feed are increased, so that the resistance against diseases, survival rate, growth rate and nutritive value of fed animals are improved; rich coenzyme Q10 and carotenoid are used as antioxidants, so that the oxygenization of polyunsaturated fatty acid can be inhibited, the stability and using effect of polyunsaturated fatty acid are improved, and the compounding effect is obvious.

Fructose-1,6-diphosphate (FDP) is used to treat patients who are undergoing coronary artery bypass grafting (CABG) surgery. Before cardiopulmonary bypass begins, a liquid that contains FDP is intravenously infused in the patient, preferably for about 10 to 30 minutes, to allow the FDP to enter the heart and lung tissue while the heart is still beating. FDP can also be added to cardioplegia solution; in addition, FDP can be injected after bypass is terminated, but if post-bypass injection is used, steps should be taken to avoid excess lactic acid accumulation, which appears to increase the risk of atrial fibrillation. To prevent or control lactic acidosis, a buffering or alkalizing agent, such as sodium bicarbonate, or an agent which reduces lactic acid formation, such as dichloroacetate, can be used. In double-blinded trials, this use of FDP substantially reduced heart damage and improved overall outcomes, as shown by lower levels of creatine kinase in blood, improvements in pumping performance, reduced requirements for vasodilator and inotropic drugs, and shorter stays in intensive care units. Certain dosages also reduced the likelihood of atrial fibrillation; however, FDP at high dosages increased the likelihood of A-fib. FDP also helped reduce pulmonary vascular resistance (PVR); this is an important finding, since pulmonary hypertension following cardiopulmonary bypass is a very difficult and often intractable problem, and is a contributing factor in nearly all deaths following CPB surgery.

A system and methods of using a multi-lumen catheter and a blood pump to increase cardiac output and blood oxygenation are described. The system diverts deoxygenated blood from the right atrium to the left atrium, through the atrial septum. The catheter is adapted for simultaneously pumping blood to and from a patient's heart. A gas exchanger may be used as part of the system to remove CO₂ and add o₂ to the blood that is pumped via the system. Components or portions of the system may be implantable in the patient.

The invention relates to a traditional Chinese pharmaceutical composition for treating cardiac failure and process for preparation, wherein the composition is prepared from the following medicinal raw materials (by weight portion): red ginseng 338-413 parts, monkshood 1013-1238 parts, poria cocos wolf 1013-1238 parts, lepidium seed 675-825 parts, notoginseng 563-688 parts, ophiopogon root 675-825 parts, the preparing process comprises mixing red ginseng, prepared aconite root, poria cocos, lepidium seed, notoginseng and ophiopogon root, charging water, grilling twice, merging the grilling liquid and filtering, concentrating the filtrate to clear grease with specific gravity of 1.07-1.10/60 Deg C, spray drying the clear grease, charging medicinal auxiliary materials, pelleting or packing capsules or making granules.

The invention relates the use of codonopsis pilosula and astragalus root composition in treating ischemic heart diseases, wherein the composition has functions for treating myocardial ischemia, myocardiac infarction, myocardiopathy, and for treating thrombogenesis, lowering blood viscosity, and reducing platelet aggregation.

The invention discloses a manufacture technology for green tea rice. A preparation method for the green tea rice comprises the following steps of: respectively extracting concentrated solutions from green tea, ginseng leaf, hawthorn leaf and stevia rebaudiana; evenly mixing the concentrated solutions with prepared tremella serous fluid and ramie oil; stirring mixture with polished round-grained rice powder to obtain pelletized material; forming by a model via granulation equipment according to puffing and extruding programs; manufacturing light yellowgreen green tea rice the same as a rice grain; and drying, tidying the grain, sterilizing and packaging.

The invention discloses a selenium-rich health wine and a production method thereof. The selenium-rich health wine consists of the following compositions in part by weight: 10 to 20 parts of tremella, 10 to 20 parts of common macrocarpium fruit, 10 to 20 parts of siberian solomonseal rhizome, 10 to 20 parts of rhodiola rosea, 10 to 20 parts of glutinous rice, 10 to 20 parts of selenium-rich malt,10 to 20 parts of distiller's yeast, 0.5 to 1 part of dried yeast, 0.1 to 0.2 part of basidiomycete and 0.5 to 1 part of seasoning. Chinese medicinal materials such as the tremella, the common macrocarpium fruit, the siberian solomonseal rhizome, the rhodiola rosea and the glutinous rice with the health care function are adopted as raw materials, and organic selenium, namely the selenium-rich malt is added into the wine to facilitate absorbing a selenium element by a human body. The brewed health wine has the effects of activating blood, removing stasis, regulating fat, reducing blood pressure, nourishing Qi, replenishing kidney, improving immunity and the like; and the added selenium-rich malt can replenish the selenium element for the human body, has the effects of resisting oxidation and aging, releasing toxin and the like and also can prevent the occurrence of cardiopathy and certain selenium-deficiency diseases.

The invention discloses a medicinal composition for treating angina pectoris of coronary heart disease. The medicinal composition consists of the following raw material medicines: cassia twig, officinal magnolia bark, humifuse euphorbia herb, Mongolian dandelion herb, cape jasmine fruit, szechuan lovage rhizome, diverse wormwood herb, processed pinellia tuber, bitter orange, rhizome of swordlike atractylodes, root of lobed kudzuvine, myrrh, arisaema consanguineum schott, cassia seed, costustoot, thinleaf milkwort root-bark, motherwort herb, silktree albizzia bark, safflower, long pepper, szechwan chinaberry fruit, fortune eupatorium herb, panax notoginseng, bezoar, snakegourd fruit, nutgrass galingale rhizome, Chinese thorowax root, mulberry fruit, lychee seeds, lucid ganoderma, dragon's blood, grassleaf sweelflag rhizome, licorice root and cyrtomium rhizome. By adopting the medicinal composition disclosed by the invention, the attack times of angina pectoris of coronary heart disease can be effectively reduced, the attack duration of angina pectoris can be shortened, the occurrence of myocardial infarction can be avoided, sudden death caused by angina pectoris can be avoided, and adverse reactions cannot be caused; and the medicinal composition is accurate in curative effect and small in toxic or side effect, ensures that the cardiac stroke volume and cardiac output can be increased, cardiac indexes can be increased, the cardiac pumping functions can be enhanced, the ventricular diastolic functions and arterial compliance can be improved, coronary arteries can be expanded and the blood flow volume of the coronary arteries can be increased, and has significant curative effects on the aspect of treating angina pectoris of coronary heart disease.